We provide you with 20 years of free, institutional-grade data for MEIP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MEIP. Explore the full financial landscape of MEIP stock.
| Reported Date | CIK | Ticker | Type |
|---|
MEI Pharma, Inc(NASDAQ:MEIP) 
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/re...
Website: http://www.meipharma.com
Founded: 2000
Full Time Employees: 51
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about MEIP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.